Synopsis: Calcitonin gene-related peptide (CGRP) is a neurotransmitter known to innervate and transmit the pain in the trigeminovascular system during a migraine attack. Ubrogepant is a CGRP receptor antagonist (gepant) found effective in reducing the pain sensitization in the dura and meningeal blood vessels. This med fact outlines a randomized interventional clinical trial titled, Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine , from The NEW ENGLAND JOURNAL OF MEDICINE . Authors : David W. Dodick, M.D., Richard B.
Lipton, et al. Study brief: Objective To evaluate the efficacy, safety, and tolerability of 2 doses of Ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack. Study type Randomized, interventional, double-blind, placebo-controlled, parallel-group, phase-3 clinical trial No. of…
